Skip to main content
logo
SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.410
-0.050 (-1.45%)
Sep 15, 2026, 4:00 PM EDT - Market closed

SAB Biotherapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
310178356330340
Market Cap Growth
1305.72%408.46%-44.79%113.36%-91.25%-
Enterprise Value
2137396627336
Last Close Price
3.413.743.796.885.9078.10

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-41.78----
PS Ratio
--26.4828.331.245.58
PB Ratio
1.331.181.351.110.968.81
P/TBV Ratio
1.441.181.351.110.968.81
P/OCF Ratio
-----170.89

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
--6.9129.321.145.51

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.020.040.180.100.190.22
Net Debt / Equity Ratio
-0.45-0.60-0.62-0.88-0.29-0.64
Net Debt / EBITDA Ratio
1.421.980.421.480.362.07
Net Debt / FCF Ratio
1.701.980.472.000.362.76
Asset Turnover
--0.020.030.360.88
Quick Ratio
8.939.132.615.231.371.56
Current Ratio
9.229.462.985.451.471.90
Return on Equity (ROE)
-11.27%14.96%-81.92%-95.51%-53.85%-44.21%
Return on Assets (ROA)
-33.46%-28.20%-41.86%-35.30%-27.37%-12.16%
Return on Capital Employed (ROCE)
-31.70%-30.20%-118.50%-52.10%-80.50%-24.50%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-7.02%7.46%-97.39%-66.52%-63.04%-5.05%
FCF Yield
-18.51%-25.67%-98.89%-39.91%-86.20%-2.64%
Buyback Yield / Dilution
-417.54%-562.28%-67.74%-26.86%-59.20%-1.21%
SEC Filings: 10-K · 10-Q